For research use only. Not for therapeutic Use.
Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency[1].
Danicamtiv selectively enhances cardiac actomyosin activity, the molecular force‐generating unit of the sarcomere, prolonging contraction while preserving actin–myosin detachment, allowing relaxation, and without impacting Ca2+ homeostasis[2].
| Catalog Number | I017248 |
| CAS Number | 1970972-74-7 |
| Synonyms | 4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide |
| Molecular Formula | C16H20F3N5O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1 |
| InChIKey | NREKKBAMVWQRES-MRXNPFEDSA-N |
| SMILES | CC(C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C |
| Reference | [1]. Sarah Fernandes, et al. Abstract 15707: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation. 2019;140:A15707 [2]. Voors AA, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649-1658. |
